CN117357446A - 一种防脱发组合物及其方法和应用 - Google Patents
一种防脱发组合物及其方法和应用 Download PDFInfo
- Publication number
- CN117357446A CN117357446A CN202311391109.8A CN202311391109A CN117357446A CN 117357446 A CN117357446 A CN 117357446A CN 202311391109 A CN202311391109 A CN 202311391109A CN 117357446 A CN117357446 A CN 117357446A
- Authority
- CN
- China
- Prior art keywords
- parts
- hair
- alopecia
- extract
- hair loss
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 201000004384 Alopecia Diseases 0.000 title claims description 47
- 231100000360 alopecia Toxicity 0.000 title claims description 35
- 230000003405 preventing effect Effects 0.000 title claims description 17
- 238000000034 method Methods 0.000 title abstract description 7
- 239000000284 extract Substances 0.000 claims abstract description 59
- 235000014653 Carica parviflora Nutrition 0.000 claims abstract description 30
- 241000195493 Cryptophyta Species 0.000 claims abstract description 30
- 230000003656 anti-hair-loss Effects 0.000 claims abstract description 22
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 241000206501 Actaea <angiosperm> Species 0.000 claims abstract description 3
- 241000243321 Cnidaria Species 0.000 claims abstract 5
- 108010023079 activin B Proteins 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 16
- 208000024963 hair loss Diseases 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 8
- 210000003780 hair follicle Anatomy 0.000 claims description 8
- 230000003676 hair loss Effects 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 5
- 230000005856 abnormality Effects 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000002453 shampoo Substances 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 25
- 210000000442 hair follicle cell Anatomy 0.000 abstract description 13
- 230000001105 regulatory effect Effects 0.000 abstract description 9
- 230000003779 hair growth Effects 0.000 abstract description 7
- 230000003658 preventing hair loss Effects 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 210000004761 scalp Anatomy 0.000 abstract description 5
- 230000003752 improving hair Effects 0.000 abstract description 4
- 230000010261 cell growth Effects 0.000 abstract description 3
- 230000004663 cell proliferation Effects 0.000 abstract description 3
- 239000005556 hormone Substances 0.000 abstract description 3
- 229940088597 hormone Drugs 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 230000004060 metabolic process Effects 0.000 abstract description 3
- 230000008439 repair process Effects 0.000 abstract description 3
- 230000001954 sterilising effect Effects 0.000 abstract description 2
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 28
- 244000132059 Carica parviflora Species 0.000 description 25
- 230000000052 comparative effect Effects 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 239000012488 sample solution Substances 0.000 description 16
- 210000004209 hair Anatomy 0.000 description 12
- 238000005303 weighing Methods 0.000 description 6
- 108010059616 Activins Proteins 0.000 description 5
- 102000005606 Activins Human genes 0.000 description 5
- 239000000488 activin Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000003698 anagen phase Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 244000025254 Cannabis sativa Species 0.000 description 3
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 3
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 235000009120 camo Nutrition 0.000 description 3
- 235000005607 chanvre indien Nutrition 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 239000011487 hemp Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 2
- 206010068168 androgenetic alopecia Diseases 0.000 description 2
- 201000002996 androgenic alopecia Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 102000003693 Hedgehog Proteins Human genes 0.000 description 1
- 108090000031 Hedgehog Proteins Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010061291 Mineral deficiency Diseases 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 230000005913 Notch signaling pathway Effects 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000030695 Sparse hair Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000003778 catagen phase Effects 0.000 description 1
- 239000007809 chemical reaction catalyst Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- -1 etc. Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 231100000640 hair analysis Toxicity 0.000 description 1
- 230000034756 hair follicle development Effects 0.000 description 1
- 230000009583 hair follicle growth Effects 0.000 description 1
- 230000003741 hair volume Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/04—Rhodophycota or rhodophyta (red algae), e.g. Porphyra
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9717—Rhodophycota or Rhodophyta [red algae], e.g. Porphyra
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
Abstract
本发明公开了一种防脱发组合物及其方法和应用。所述的防脱发组合物由以下重量份原料组成：活性素B 1～10份、水解珊瑚藻提取物10～50份和总状升麻根提取物10～30份。本发明提供的防脱发组合物分别从调节毛囊细胞信号通路、提高毛囊细胞活性、调节毛囊细胞生长代谢、抑制雄性激素、炎症修复及调节头皮微生态(杀菌消炎)的多个角度作用，促进毛囊细胞增殖和毛发增长，发挥显著的防脱发功效，显著优于单一组分(或其他形式的组合)，并且对人体安全、无副作用。
Description
技术领域
本发明属于日化技术领域，具体涉及一种防脱发组合物及其方法和应用。
背景技术
脱发是指各种因素引起头发脱落的现象，一般分为生理性脱发和非生理性脱发。头发生长呈周期性，包括生长期、退行期和休止期。正常情况下，头发在生长期生长到一定程度后会进入退行期和休止期，出现生理性的脱落。由于进入退行期与新进入生长期的头发处于动态平衡，故能维持正常的发量。通常每人每天会掉落50～100根头发，这种由于头发到达正常生长周期中的休止期而脱落的现象称之为生理性脱发。若头发每天脱落数量超过了100根，头发生长动态平衡通常就被打破，头发会变得稀疏，甚至秃头，不仅影响容貌，还会给人带来心理压力和精神负担。这种头发大量异常脱落导致头发稀疏或发际线后移等严重影响患者外表形象的现象称为非生理性脱发，亦称病理性脱发。
按照病理性脱发发生的主要原因可以将其分为五类：雄激素性脱发、免疫缺陷性脱发、损伤性脱发、营养异常性脱发和药物性脱发。针对病理性脱发人群的不断增多，市场上出现了品类繁多的防脱发产品。这些产品大致可为两类，一类产品以中药医理论为基础，采用复合草本提取物，依据配方原料的不同，对应产生滋养或控油等效果，以达到防止脱发的目的，但从消费者使用后反馈的情况分析，绝大部分的产品效果不甚明显；另一类产品为添加了西药的头发护理产品，主要以西地那非、米诺地尔等作为活性成分，此类产品使用初期具有明显的防脱生发功效，但是长期使用会有明显的副作用(性功能障碍、血压过低等)，结果得不偿失。
发明内容
为解决现有的防脱发产品效果不佳，或存在副作用大的缺陷。本发明提供了一种防脱发组合物，该组合物通过调节毛囊细胞信号通路、提高毛囊细胞活性、调节毛囊细胞生长代谢、抑制雄性激素、炎症修复及调节头皮微生态的方式促进毛囊细胞增殖和毛发增长，发挥显著的防脱发功效，并且对人体安全、无副作用。
本发明的技术方案为：
一种防脱发组合物，包括以下原料：活性素B、水解珊瑚藻提取物和总状升麻根提取物。
进一步的，所述的防脱发组合物，由以下重量份原料组成：活性素B1～10份、水解珊瑚藻提取物10～50份和总状升麻根提取物10～30份。
进一步的，所述的防脱发组合物，由以下重量份原料组成：活性素B10份、水解珊瑚藻提取物40份和总状升麻根提取物20份。
又一方面，本发明还提供所述的防脱发组合物在制备防治脱发的产品中的应用。
进一步的，所述的脱发包括各种原因引起的毛囊异常导致的脱发。
进一步的，所述的产品包括洗发日用品或外用药品。
进一步的，所述的产品的剂型包括透明液体、乳液、膏体或凝胶。
进一步的，所述的防脱发组合物在防治脱发产品中的添加量为2-10wt％。
又一方面，本发明还提供一种防治脱发的产品，其包含有效量的作为活性成分的防脱发组合物。
又一方面，本发明还提供一种防脱发组合物的制备方法，包括将活性素B、水解珊瑚藻提取物和总状升麻根提取物混合的步骤。
活化素(Activin,ACT)是转化生长因子-β(TGF-β)的超家族成员，参与多种细胞的生长调节，其包括活化素A、活化素B、活化素C和活化素E四种分子结构。其中活化素B已被证实具有促进毛囊发育和生长的作用，推测其机理为：活化素B可以激活Notch信号通路以加速音猬因子(Sonic Hedgehog,Shh)蛋白的产生，诱导毛囊从休止期到生长期转变，并阻止毛囊从生长期到退行期的转变，从而促进毛发的生长。
水解珊瑚藻提取物，INCI名称为：水/水解珊瑚藻提取物/苯氧乙醇(产品名：OLIGOPHYCOCORAIL SPE)，购自法国赛比克(Seppic)公司，其富含镁、锌、锰、钙等微量元素，为头发补充微量元素，同时可作为细胞活化剂和生物反应催化剂，解决矿物质缺乏引起的脱发问题。
总状升麻根提取物(产品名：PHYTO-AGETM)，CAS号为：84776-26-1，购自法国赛比克(Seppic)公司，其可产生类雌激素样效果，调节内分泌平衡，有助于防治雄激素性脱发；其还具有很好的杀菌消炎、抗油脂氧化作用，能减轻毛囊炎性反应，缓解毛囊损伤，牢固发根、充养毛发。
本发明提供的防脱发组合物分别从调节毛囊细胞信号通路、提高毛囊细胞活性、调节毛囊细胞生长代谢、抑制雄性激素、炎症修复及调节头皮微生态(杀菌消炎)的多个角度作用，促进毛囊细胞增殖和毛发增长，发挥显著的防脱发功效，显著优于单一组分(或其他形式的组合)，并且对人体安全、无副作用。
具体实施方式
以下实施例是对本发明的进一步说明，而不是对本发明的限制。
实施例1
一种防脱发组合物，由以下重量份原料组成：活性素B10份、水解珊瑚藻提取物40份和总状升麻根提取物20份。制备步骤：分别称取配方量的活性素、水解珊瑚藻提取物和总状升麻根提取物，将其搅拌混合，即得。
实施例2
一种防脱发组合物，由以下重量份原料组成：活性素B1份、水解珊瑚藻提取物20份和总状升麻根提取物20份。制备步骤：分别称取配方量的活性素、水解珊瑚藻提取物和总状升麻根提取物，将其搅拌混合，即得。
实施例3
一种防脱发组合物，由以下重量份原料组成：活性素B 5份、水解珊瑚藻提取物10份和总状升麻根提取物30份。制备步骤：分别称取配方量的活性素、水解珊瑚藻提取物和总状升麻根提取物，将其搅拌混合，即得。
实施例4
一种防脱发组合物，由以下重量份原料组成：活性素B1份、水解珊瑚藻提取物50份和总状升麻根提取物20份。制备步骤：分别称取配方量的活性素、水解珊瑚藻提取物和总状升麻根提取物，将其搅拌混合，即得。
实施例5
一种防脱发组合物，由以下重量份原料组成：活性素B 5份、水解珊瑚藻提取物30份和总状升麻根提取物10份。制备步骤：分别称取配方量的活性素、水解珊瑚藻提取物和总状升麻根提取物，将其搅拌混合，即得。
实施例6、人体安全性斑贴测试：
1、样品配制：
(1)分别称取0.1g活性素B、1g水解珊瑚藻提取物、1g总状升麻根提取物。
(2)将活性素B和水解珊瑚藻提取物溶于适量的去离子水，得到溶液A；将总状升麻根提取物溶于DMSO，得到溶液B；
(3)将溶液A和溶液B混合，并加入去离子水定容至100mL，得到样品溶液A。
参照上述的配制步骤，制备样品溶液B，每100mL样品溶液B含有1g活性素B、5g水解珊瑚藻提取物、3g总状升麻根提取物。
2、实验步骤：
选取面积不超过50mm2，深度约1mm的合格斑贴器具，在9名志愿测试者的背部做斑贴测试，将样品溶液A、样品溶液B以及空白对照样品(去离子水)按顺序放置在斑贴器具上，各取样0.05mL，然后用低致敏胶带贴到每一位的测试者的背部进行测试，用手掌轻压使之均匀的贴敷于皮肤上，持续24h。
实验结果：测试24h后，去除受试者背部的斑贴器材后30min后观察结果，结果显示，受试者的背部皮肤没有一例出现红、刺痛的现象或者疑似红斑的反应，说明本发明的防脱发组合物溶液是安全的，没有任何不良反应现象出现。
实施例7、防脱发效果评价
1、样品配制：
参照实施例6的方法分别配制如下样品溶液：
样品A：每100mL样品溶液含有1g活性素B、4g水解珊瑚藻提取物、2g总状升麻根提取物。
样品B：每100mL样品溶液含有0.5g活性素B、1g水解珊瑚藻提取物、3g总状升麻根提取物。
样品C：每100mL样品溶液含有0.5g活性素B、3g水解珊瑚藻提取物、1g总状升麻根提取物。
样品D：每100mL样品溶液含有0.1g活性素B、5g水解珊瑚藻提取物、2g总状升麻根提取物。
比较样品E：每100mL样品溶液含有1g活性素B。
比较样品F：每100mL样品溶液含有4g水解珊瑚藻提取物。
比较样品G：每100mL样品溶液含有2g总状升麻根提取物。
比较样品H：每100mL样品溶液含有1g活性素B、4g水解珊瑚藻提取物。
比较样品I：每100mL样品溶液含有1g活性素B、2g总状升麻根提取物。
2、实验步骤：
选取90例脂溢性脱发志愿受试者，年龄30～55岁。将受试者随机分为9组，每组10例，分别使用样品A～D、比较样品E～I进行涂抹，早晚各使用一次，每次取2mL样品溶液涂抹至脱发处头皮，并按摩5～10min，连续使用1个月。试验期间不使用任何对结果有影响的其他化妆品、药物和保健品。分别于使用前、使用后采用毛囊毛发分析仪检测受试者脱发处(面积4CM×4CM)的毛囊密度变化，取平均值，结果见表1。同时评估受试者在使用前后脱发症状的改善情况，结果见表2。
表1毛囊密度变化评价结果(个/CM2)
| 组别 | 使用前 | 使用后 | 改善率％ |
| 样品A | 58.2 | 96.0 | 64.9 |
| 样品B | 60.5 | 94.9 | 56.9 |
| 样品C | 61.7 | 95.2 | 54.3 |
| 样品D | 59.3 | 96.4 | 62.6 |
| 比较样品E | 63.6 | 83.4 | 31.1 |
| 比较样品F | 67.2 | 71.7 | 6.7 |
| 比较样品G | 57.4 | 64.3 | 12.0 |
| 比较样品H | 64.5 | 93.0 | 44.2 |
| 比较样品I | 58.8 | 87.3 | 48.5 |
结果显示，样品A～D增加头发毛囊密度的效果优于比较样品E～I，该结果表明，本发明的防脱发组合物促进毛囊细胞增殖的效果优于单一组分(或其他形式的组合)。本发明的防脱发组合物具有生发功效，且协同作用显著。
表2脱发情况变化评价结果(以评价人数计)
| 组别 | 没有变化 | 轻微改善 | 显著改善 | 停止掉发 |
| 样品A | 0 | 2 | 5 | 3 |
| 样品B | 0 | 3 | 6 | 1 |
| 样品C | 0 | 4 | 5 | 1 |
| 样品D | 0 | 3 | 5 | 2 |
| 比较样品E | 2 | 2 | 5 | 1 |
| 比较样品F | 3 | 5 | 2 | 0 |
| 比较样品G | 2 | 4 | 3 | 1 |
| 比较样品H | 1 | 4 | 4 | 1 |
| 比较样品I | 1 | 2 | 6 | 1 |
结果显示，样品A～D防脱发的效果优于比较样品E～I，该结果表明，本发明的防脱发组合物改善脱发症状的效果优于单一组分(或其他形式的组合)。本发明的防脱发组合物具有优异的防脱发功效，且协同作用显著。
以上仅是本发明的优选实施方式，应当指出的是，上述优选实施方式不应视为对本发明的限制，本发明的保护范围应当以权利要求所限定的范围为准。对于本技术领域的普通技术人员来说，在不脱离本发明的精神和范围内，还可以做出若干改进和润饰，这些改进和润饰也应视为本发明的保护范围。
Claims (10)
1.一种防脱发组合物，其特征在于，包括以下原料：活性素B、水解珊瑚藻提取物和总状升麻根提取物。
2.根据权利要求1所述的防脱发组合物，其特征在于，由以下重量份原料组成：活性素B1～10份、水解珊瑚藻提取物10～50份和总状升麻根提取物10～30份。
3.根据权利要求2所述的防脱发组合物，其特征在于，由以下重量份原料组成：活性素B10份、水解珊瑚藻提取物40份和总状升麻根提取物20份。
4.权利要求1-3任一所述的防脱发组合物在制备防治脱发的产品中的应用。
5.根据权利要求4所述的应用，其特征在于，所述的脱发包括各种原因引起的毛囊异常导致的脱发。
6.根据权利要求4所述的应用，其特征在于，所述的产品包括洗发日用品或外用药品。
7.根据权利要求6所述的应用，其特征在于，所述的产品的剂型包括透明液体、乳液、膏体或凝胶。
8.根据权利要求4所述的应用，其特征在于，所述的防脱发组合物在防治脱发产品中的添加量为2-10wt％。
9.一种防治脱发的产品，其特征在于，包含有效量的作为活性成分的如权利要求1-3任一所述的防脱发组合物。
10.一种防脱发组合物的制备方法，其特征在于，包括将活性素B、水解珊瑚藻提取物和总状升麻根提取物混合的步骤。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311391109.8A CN117357446A (zh) | 2023-10-25 | 2023-10-25 | 一种防脱发组合物及其方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311391109.8A CN117357446A (zh) | 2023-10-25 | 2023-10-25 | 一种防脱发组合物及其方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117357446A true CN117357446A (zh) | 2024-01-09 |
Family
ID=89405481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311391109.8A Pending CN117357446A (zh) | 2023-10-25 | 2023-10-25 | 一种防脱发组合物及其方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117357446A (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100860349B1 (ko) * | 2007-04-27 | 2008-09-25 | (주) 신현대한방연구소 | 생약추출물을 함유하는 모발생장촉진용 조성물 |
| DE102009027942A1 (de) * | 2009-07-22 | 2010-05-20 | Henkel Ag & Co. Kgaa | Haarbehandlungsmittel enthaltend einen Extrakt aus Cimicifuga |
| CN111803613A (zh) * | 2020-08-12 | 2020-10-23 | 贵州松桃信仁苗药有限公司 | 一种治疗脱发及头发再生的中药组合物 |
| CN112336779A (zh) * | 2019-08-09 | 2021-02-09 | 宋国强 | 一种防脱发生发激活素 |
| CN115537393A (zh) * | 2022-12-05 | 2022-12-30 | 广州优特佳生物科技发展有限公司 | 一种促进毛发生长的脐带间充质干细胞定向分泌组的制备方法和应用 |
-
2023
- 2023-10-25 CN CN202311391109.8A patent/CN117357446A/zh active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100860349B1 (ko) * | 2007-04-27 | 2008-09-25 | (주) 신현대한방연구소 | 생약추출물을 함유하는 모발생장촉진용 조성물 |
| DE102009027942A1 (de) * | 2009-07-22 | 2010-05-20 | Henkel Ag & Co. Kgaa | Haarbehandlungsmittel enthaltend einen Extrakt aus Cimicifuga |
| CN112336779A (zh) * | 2019-08-09 | 2021-02-09 | 宋国强 | 一种防脱发生发激活素 |
| CN111803613A (zh) * | 2020-08-12 | 2020-10-23 | 贵州松桃信仁苗药有限公司 | 一种治疗脱发及头发再生的中药组合物 |
| CN115537393A (zh) * | 2022-12-05 | 2022-12-30 | 广州优特佳生物科技发展有限公司 | 一种促进毛发生长的脐带间充质干细胞定向分泌组的制备方法和应用 |
Non-Patent Citations (1)
| Title |
|---|
| 查布立昂: "海洋植物与蓝色化妆品", 日用化学品科学, vol. 29, no. 4, 30 April 2006 (2006-04-30), pages 26 - 31 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Semalty et al. | Hair growth and rejuvenation: an overview | |
| KR101509608B1 (ko) | 두피 및 모발 상태 개선용 조성물 | |
| WO2016046848A2 (en) | Novel formulation of concentrated natural actives in oil-water microemulsion for hair fall prevention and increase in hair density | |
| US9839606B2 (en) | Formulation for treatment of hairs | |
| CN110368397A (zh) | 一种防止脱发促进毛发生长的外用组合物及其制备方法 | |
| CN112870333A (zh) | 一种改善人脱发生发的组合物、制剂及制备方法和应用 | |
| CN114432198B (zh) | 一种健发精华液及其使用方法 | |
| CN113797142A (zh) | 一种薰衣草乳香黑曜精华液配方及其制备方法 | |
| CN117357446A (zh) | 一种防脱发组合物及其方法和应用 | |
| JPS63145216A (ja) | 育毛養毛等美髪料 | |
| EP3638198B1 (de) | Zusammensetzung zur verhinderung von haarausfall und wachstumsförderung von haaren | |
| CA2132170A1 (en) | Medicine for the treatment of alopecia and skin diseases | |
| KR20210083236A (ko) | 탈모 방지 및 두피 개선용 조성물 | |
| WO2013020719A2 (en) | New use of compositions to delay the onset of the catagen phase of the hair | |
| CN114886937B (zh) | 一种具有乌发健发功能的天然产物提取物组合物及其用途 | |
| Sharma et al. | Concept of hair and hair diseases in Ayurveda | |
| CN114948940B (zh) | 一种具有乌发健发功能的天然产物单体组合物及其用途 | |
| JP2004067573A (ja) | 養育毛剤 | |
| US20240041963A1 (en) | A nutraceuticals formulation with an enhanced organoleptic properties used for scalp and hair care | |
| CN115252506B (zh) | 一种防脱生发组合物及其制备方法和应用 | |
| KR0154210B1 (ko) | 두발 화장품 조성물 | |
| KR0152362B1 (ko) | 생약성분 양모제 제조방법 | |
| CN117379465B (zh) | 一种生发益发组合物及其制备方法和应用 | |
| CN114848558B (zh) | 一种防脱生发、白发转黑发的生发乌发液及其制备方法 | |
| CN116270382A (zh) | 一种具有防脱去屑控油止痒功效的头皮护理组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20240523 Address after: No. 82, Shinan Village, Meilin Village, Longqiao Town, Lujiang County, Hefei City, Anhui Province, 231551 Applicant after: Shi Baolan Country or region after: China Address before: 510000, Room 201, 2nd Floor, Building B, Zhongqian Zhiben Grass Industrial Park, Xiangxi Avenue, Xiamao 19th Community, Baiyunhu Street, Baiyun District, Guangzhou City, Guangdong Province Applicant before: Guangzhou Biyan Cosmetics Co.,Ltd. Country or region before: China |